Morningstar

Medpace Holdings Inc MEDP

Morningstar Rating
Unlock
Stock XNAS Rating as of
$331.44 +5.18 (1.59%)
View Full Chart
As of Delayed Price Pre-Open: $329.74 −1.69

Company Report

View Archive

Medpace Benefits From Strong Clinical Trial Outsourcing Demand

Rachel Elfman

Medpace is a global late-stage contract research organization, or CRO, that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. The company was founded over 30 years ago in Cincinnati. It is principally based in the US but also operates in Europe, Asia, South America, Africa, and Australia.

Read Full Report

Price vs Fair Value

View History
MEDP is trading within a range we consider fairly valued.
Price
$331.44
Fair Value
$166.00
Uncertainty
Medium
1-Star Price
$165.90
5-Star Price
$642.80
Economic Moat
Prlhnby
Capital Allocation
Vytvpnyh

Bulls Say, Bears Say

Bulls

Medpace's small and midsize biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.

Bears

Significant pullbacks in biotech funding or declines in outsourcing penetration rates could have a material impact on Medpace's growth.

Show More

News

View All

Trading Information

Previous Close Price
$326.26
Day Range
$322.09–334.74
52-Week Range
$227.21–459.77
Bid/Ask
$320.01 / $400.00
Market Cap
$10.28 Bil
Volume/Avg
160 / 319,768

Key Statistics

Price/Earnings (Normalized)
31.18
Price/Sales
5.21
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
5,800
Website
https://www.medpace.com

Competitors

Valuation

View More
Metric
MEDP
FTRE
IQV
Price/Earnings (Normalized)
 31.1823.0422.35
Price/Book Value
 13.461.226.38
Price/Sales
 5.210.612.86
Price/Cash Flow
 27.51—17.43
Price/Earnings
MEDP
FTRE
IQV

Financial Strength

Metric
MEDP
FTRE
IQV
Quick Ratio
 0.821.020.75
Current Ratio
 0.881.190.85
Interest Coverage
 —−0.503.10
Quick Ratio
MEDP
FTRE
IQV

Profitability

Metric
MEDP
FTRE
IQV
Return on Assets (Normalized)
 21.49%0.74%7.37%
Return on Equity (Normalized)
 62.19%1.86%31.57%
Return on Invested Capital (Normalized)
 47.95%4.58%12.80%
Return on Assets
MEDP
FTRE
IQV

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
JsxhqwtnmYttv$234.7 Bil
 Danaher Corp
DHR
DwtqtpfytYskbqq$198.9 Bil
 IQVIA Holdings Inc
IQV
CkvszkyjYynhjs$42.8 Bil
 Agilent Technologies Inc
A
VsmlfjndqfRgp$42.5 Bil
 IDEXX Laboratories Inc
IDXX
FmgzfjfkHlfd$42.1 Bil
 Mettler-Toledo International Inc
MTD
PfjthmpxnYyrxj$31.4 Bil
 Icon PLC
ICLR
SsftstsgFwsgfgj$23.7 Bil
 Waters Corp
WAT
ZrkgyrpwZqcq$21.2 Bil
 Illumina Inc
ILMN
KykhyphjgPkbcxz$20.7 Bil
 Labcorp Holdings Inc
LH
TzpqkdlwvTmnbyk$18.6 Bil

Sponsor Center